Latest Revascularization Stories
A systematic review of medical evidence has determined drug-eluting stents (DES) outperform bare metal stents (BMS) for revascularization of chronic total occlusions.
Researchers at the Stanford University School of Medicine, in collaboration with BioParadox, Inc., have published data supporting the use of platelet-rich plasma as a promising biologic treatment for myocardial infarction (heart attack).
Treatment that included early surgical procedures to open blocked arteries resulted in better blood flow to the heart than aggressive medical treatment alone in patients with both diabetes and heart disease.
Researchers from the Cardiac & Vascular Institute at NYU Langone Medical Center will present at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium on September 21-25, 2010 in Washington, DC.
IRVINE, Calif., July 15 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTCQB: CGCP) today announced that Executive Chairman Paul J. McCormick will present a corporate overview during the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on Tuesday, July 20, 2010, at 11:00 a.m.
NEW YORK, July 14 /PRNewswire-FirstCall/ -- Cardiogenesis Corp.
IRVINE, Calif., June 23 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTCQB: CGCP), today announced that it is scheduled to present at the New York OneMedForum Emerging Company Finance Conference to be held June 29-30, 2010 at the Roosevelt Hotel. Executive Chairman Paul J.
- A poem in which the author retracts something said in an earlier poem.